key: cord-0862815-o86wki37
authors: Servellita, Venice; Syed, Abdullah M.; Morris, Mary Kate; Brazer, Noah; Saldhi, Prachi; Garcia-Knight, Miguel; Sreekumar, Bharath; Khalid, Mir M.; Ciling, Alison; Chen, Pei-Yi; Kumar, G. Renuka; Gliwa, Amelia S.; Nguyen, Jenny; Sotomayor-Gonzalez, Alicia; Zhang, Yueyuan; Frias, Edwin; Prostko, John; Hackett, John; Andino, Raul; Wadford, Debra A.; Hanson, Carl; Doudna, Jennifer; Ott, Melanie; Chiu, Charles Y.
title: Neutralizing immunity in vaccine breakthrough infections from the SARS-CoV-2 Omicron and Delta variants
date: 2022-03-18
journal: Cell
DOI: 10.1016/j.cell.2022.03.019
sha: f0d3c75b9cace8cd09845b0ecb8206f8c2508c06
doc_id: 862815
cord_uid: o86wki37

Virus-like particle (VLP) and live virus assays were used to investigate neutralizing immunity against Delta and Omicron SARS-CoV-2 variants in 259 samples from 128 vaccinated individuals. Following Delta breakthrough infection, titers against WT rose 57-fold and 3.1-fold compared to uninfected boosted and unboosted individuals, respectively, versus only a 5.8-fold increase and 3.1-fold decrease for Omicron breakthrough infection. Among immunocompetent, unboosted patients, Delta breakthrough infections induced 10.8-fold higher titers against WT compared to Omicron (p=0.037). Decreased antibody responses in Omicron breakthrough infections relative to Delta were potentially related to a higher proportion of asymptomatic or mild breakthrough infections (55.0% versus 28.6%, respectively), which exhibited 12.3-fold lower titers against WT compared to moderate-severe infections (p=0.020). Following either Delta or Omicron breakthrough infection, limited variant-specific cross-neutralizing immunity was observed. These results suggest that Omicron breakthrough infections are less immunogenic than Delta, thus providing reduced protection against reinfection or infection from future variants.

Variants of concern have emerged throughout the COVID-19 (Coronavirus Disease 2019) pandemic, 48 causing multiple waves of infection (Dyson et al. 2021 ). The Omicron (B.1.1.529) variant has been shown to be 49 highly transmissible with decreased susceptibility to therapeutic monoclonal antibodies and neutralizing 50 antibodies conferred by vaccination or prior infection (Flemming 2022; VanBlargan et al. 2022 ). These 51 characteristics are likely due to more than 30 mutations in the spike protein (Cao et al. 2021 ). Omicron has 52 spread to become the predominant circulating lineage worldwide as of February 2022 amidst lower background 53 levels of Delta (B.1.617.2) variant infection (Gangavarapu et al., 2020) . The surge in Omicron led to a 54 temporary reinstatement of public health interventions to reduce transmission and a renewed focus on 55 vaccination efforts, although evidence to date suggests that Omicron causes less severe disease than other 56

To investigate neutralizing antibody responses and the extent of cross-neutralizing immunity, we 106 analyzed plasma samples from 60 patients with confirmed SARS-CoV-2 breakthrough infections (Table S1) . 107 Of the 60 cases, 28 and 20 were found to be associated with Delta and Omicron breakthrough infections, 108

respectively, by viral whole-genome sequencing. For the remaining 12 cases, we were unable to confirm the 109 lineage because of a lack of respiratory swab sample or insufficient viral genome coverage for definitive 110 identification. Of the 12 cases, 11 were presumptively identified as Delta breakthrough cases because they were 111 collected between July 30 and December 1, 2021, during a period when Delta accounted for 97. immunocompromised (Table S1 ). The number of days between sample collection and symptom onset or PCR 117 test positivity, whichever was earlier, ranged from 1 to 55 days (median = 14 days). 118

Using VLP assays, we found that patients with Delta breakthrough infections (n=39), 5 of whom were 119 boosted, had higher median VLP neutralization titers against WT of 57-fold (14,835 versus 262) and 3.1-fold 120 (14,835 versus 4,727) compared to those from unboosted and boosted individuals, respectively ( Figure 1A and  121 B, left and Figure 2A ). In addition, neutralization titers against Delta rose to the same level as WT in the live 122 virus assay ( Figure 2B , left). Cross-neutralizing activity against Omicron was also observed but was limited as 123 the 31.4-fold and >46.8-fold reductions in Omicron neutralization relative to WT for the VLP and live assays 124 (Figure 2A and B, middle) , respectively, were comparable to those seen in uninfected, unboosted individuals 125 (33.3-43.5-fold reductions) ( Figure 1G , 14-30 days and 30-60 days). The proportion of Delta breakthrough 126 individuals with neutralizing antibodies against Omicron above an NT50 cutoff of 40 was calculated at ~75% 127 and ~43% for the VLP and live virus assays, respectively (Figure 2A and B, right) 128 Among the 21 total Omicron breakthrough infections in the study, plasma samples from 14 cases, 4 in 129 boosted individuals, were available for both VLP and live virus neutralization studies. In contrast to Delta, 130 J o u r n a l P r e -p r o o f 6 Omicron breakthrough infections exhibited much smaller increases in neutralizing titers against WT, 5.8-fold 131

(1,524 versus 262) compared to unboosted individuals and to about one-third of the titers achieved from 132 boosting (1,524 versus 4,727) ( Figure 1A and C, left and 2C). Neutralizing titers against Omicron in Omicron 133 breakthrough individuals were 3.9-6.6-fold lower than WT ( Figure 2C and D, middle) . Omicron breakthrough 134 infection resulted in ~85% ( Figure 2C , right) and ~65% ( Figure 2D , right) of individuals having neutralizing 135 antibodies against Omicron above an NT50 cutoff of 40 for the VLP and live virus assays, respectively, 136

approaching the proportion of those having neutralizing antibodies to Delta (~85% for both assays) ( Figure 2C  137 and D, right). In contrast, cross-neutralization against Delta in Omicron breakthrough infections was limited, 138 with 3.3-fold and 2.2-fold reductions in titers for the VLP and live assays ( Figure 2C and D, left), respectively, 139 comparable to those observed previously in uninfected vaccinated individuals (2.7-3.0 fold) ( Figure 1A) . Thus, 140

for both Delta and Omicron breakthrough infections, the extent of conferred cross-neutralizing immunity 141

beyond an increase in neutralization titers against WT was limited. 142

Next, a head-to-head comparison of neutralization titers from Omicron and Delta breakthrough 143

infections was performed using available samples collected 4 to 32 days after symptom onset or PCR test 144 positivity (n=55, 35 Delta and 20 Omicron out of 60 total breakthrough infections) (Figure 3 ) . The cohorts  145 were largely comparable, exhibiting no significant differences with respect to advanced age, sex, disease 146 severity, immune status, and collection date relative to time of symptom onset or PCR test positivity (Table 1) . 147

Kernel density plots showed that available samples from Omicron breakthrough infections were collected a 148 median 4 days earlier than Delta. These differences were not significant (p=0.34-0.38), and the distribution of 149

Omicron cases was skewed toward later time points ( Figure 3A and B infections, a rise in neutralization titers occurred typically within 7 days after symptom onset or PCR test 160 positivity ( Figure 3C ). The rate of rise in immunocompromised, unboosted patients was 1.4-fold higher (, or 161 slope coefficient of 551 versus 389) for Delta breakthrough infections compared to Omicron ( Figure 3C , 162 insets).

Increased clinical severity of the breakthrough infection is associated with higher neutralizing antibody 165 titers 166

Visual inspection of the antibody neutralization plots revealed generally higher titers in moderate-severe 167 compared to asymptomatic or mild infections, regardless of the infecting variant ( Figure 3A and B, middle).

Moderate-severe breakthrough infections from Delta or Omicron were found to elicit 5.0-fold higher 169

neutralizing antibody titers (20,121 versus 3,982, p=0.20) compared to asymptomatic or mild infections ( Figure  170 3A, right). When considering only the subset of immunocompetent, unboosted patients ( Figure spike IgG titers of 10 3 -10 4 ( Figure 4B , middle row) and >10 5 ( Figure 4B, comparable to the 7.4-fold reduction that we observed using the VLP assay. However, these modest reductions 208 are likely offset by the substantial increase in neutralizing antibody titers against WT conferred by the booster 209 dose that we observed in the current study, which also has been reported by Gruell, et al. (2022) . Taken  210 together, these results indicate that booster immunization provides robust neutralizing immunity against the 211

Omicron variant and highlight the importance of vaccine boosters in enhancing immunity to both existing and 212 novel variants. 213

Our findings have implications regarding the likelihood that Omicron infections will provide mass 214

immunization on the population level against SARS-CoV-2. Widespread infections from Omicron globally in 215 both vaccinated and unvaccinated persons have been reported, although Omicron has been shown to cause 216 milder disease with reduced risk of hospitalization and death relative to prior lineages (Wolter et al., 2022) . In 217 addition, epidemiologic data to date suggest that Omicron has outcompeted more pathogenic circulating 218 variants such as Delta (Gangavarapu et al., 2020) . These observations raise the prospect that Omicron may be a 219 harbinger of the end of the pandemic as SARS-CoV-2 becomes an endemic virus and broad swaths of the 220 population acquire vaccine-mediated and/or natural immunity. However, in the current study, we found that 221

Omicron breakthrough infections generate a slower rise in and lower levels of neutralizing antibodies than 222

Delta. A muted neutralizing antibody response with Omicron breakthrough infections relative to Delta may be 223 due to an increased proportion of asymptomatic or mild infections in the Omicron cohort (55.0% versus 28.6% 224

for Delta, p=0.083), or decreased replication and virulence along with attenuated disease associated with 225

Omicron infection (Halfmann, et In the current study, live virus neutralization studies showed 2.5-fold lower titers than those using VLPs, 232

which are similar to spike-pseudotyped viruses. Most SARS-CoV-2 neutralization studies reported to date have 233 used pseudoviruses because the protocols for running these assays have been reliable, safe, and convenient. Of 234 note, the VLPs used in this study incorporate all the Omicron-specific mutations found in the structural spike, The utility of the FDA authorized serologic assay results as correlates of immune protection with respect 246 to infection from different variants is still under investigation (Gilbert et al. 2021 ). Here we found that spike 247

IgG quantitative and neutralizing antibody results are less correlated with Delta and Omicron infections and 248 thus less predictive of neutralizing immunity. The degree of correlation was inversely related to the extent of 249 neutralizing antibody evasion associated with the variant, which is to be expected since the IgG quantitative 250 assay targets the spike protein from an ancestral WA-1 lineage. Despite the presence of multiple spike 251 mutations, measured antibody levels of 10 3 -10 4 for Delta and >10 5 for Omicron still reliably predicted 252 neutralization. Nevertheless, serologic assays tailored to individual variants or assays directly measuring 253 neutralization will likely be needed for more accurate assessments of neutralizing immunity. 254 J o u r n a l P r e -p r o o f (accession numbers included in Table S1 ). Scripting code used for the data analysis and visualization, SARS-286

CoV-2 genome FASTA files, and 

is the director of the UCSF-Abbott Viral Diagnostics and Discovery and receives research support for 530 SARS-CoV-2 studies from Abbott Laboratories

Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies

Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent

CoV-2 and a Clinical Isolate of SARS-CoV-2

SARS-CoV-2 B.1.1.529 (Omicron) Variant -United States

Variants (California Department of Public Health)

Outcomes of laboratory-confirmed SARS-CoV-2 infection in the 550

Omicron-driven fourth wave compared with previous waves in the Western Cape Province, South Africa. 551 medRxiv

Possible future waves of SARS-CoV-2 infection generated by variants of concern with a 555 range of characteristics

Omicron, the great escape artist

Immune correlates analysis of the mRNA-1273 COVID-19 565 vaccine efficacy clinical trial

An amplicon-based sequencing framework for accurately 569 measuring intrahost virus diversity using PrimalSeq and iVar

2022) mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-574 2 Omicron variant

SARS-CoV-2 Omicron virus causes attenuated disease in mice and 578 hamsters

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is 582 Blocked by a Clinically Proven Protease Inhibitor

SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo. 586 Nature

Viral Dynamics of SARS-CoV-2 Variants in Vaccinated and Unvaccinated 590 Persons

SARS-CoV-2 variant exposures elicit antibody responses with differential cross-594 neutralization of established and emerging strains including Delta and Omicron. The Journal of Infectious 595 Diseases

598 (2022) Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2

Multiplex PCR method for MinION and Illumina sequencing of 603 Zika and other virus genomes directly from clinical samples

A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology

Predominance of antibody-resistant SARS-CoV-2 variants in 611 vaccine breakthrough cases from the San Francisco Bay Area

Rapid assessment of SARS-CoV-2-evolved variants using virus-like 616 particles

Omicron mutations enhance infectivity and reduce antibody neutralization of SARS-620

CoV-2 virus-like particles. medRxiv

Association between mRNA vaccination and COVID-19 hospitalization 624 and disease severity

An infectious SARS-CoV-2 B.1.1.529 Omicron virus 628 escapes neutralization by therapeutic monoclonal antibodies

SARS-CoV-2 breakthrough infections elicit potent, broad, and 632 durable neutralizing antibody responses

Early assessment of the clinical severity of the SARS-CoV-2 omicron

South Africa: a data linkage study

Three exposures to the spike protein of SARS-CoV-2 by either infection or 638 vaccination elicit superior neutralizing immunity to all variants of concern

In breakthrough infections, variant-specific cross-neutralizing immunity is limited

Higher antibody titers are observed in severe versus mild breakthrough infections

Delta breakthroughs exhibited 10.8X higher antibody titers compared to Omicron

In comparing breakthrough infections from the SARS-CoV-2 Delta and Omicron variants, the latter, though milder than Delta infections, were associated with lower antibody titers and limited cross-neutralizing immunity, suggesting reduced protection against re-infection or infection from a future variant

We thank Baolin Wang for her assistance in preparing SARS-CoV-2 genomic sequencing libraries. We thank 505 the staff at the UCSF Clinical Laboratories (